There’s new hope for cancer patients and their families thanks to the Ochsner Precision Cancer Therapies Program. It’s the region’s only program dedicated to bringing early phase clinical trials to the Gulf South. That means you can get access to advanced, groundbreaking cancer treatments early.
HiddenHind
© Ochsner Health System | Notice of Privacy Practices
Ochsner accepts all major insurances.
Ochsner is a 501(c)3 not-for-profit organization, founded on providing the best patient care, research, and education.
We are one of the country’s largest non-university based academic medical centers.
Ochsner is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, age, national origin or ancestry, citizenship, sexual orientation, gender identity, veteran status, disability or any other protected characteristic under applicable law.
Hidden text for Hind Bold
Leading the Way in Cancer Care
The Gayle and Tom Benson Cancer Center has been awarded
three-year accreditation
from the Commission on Cancer of the American College of Surgeons.
Ochsner is ranked No. 1 in the New Orleans metro area and recognized among the Best Hospitals in southeastern Louisiana by U.S. News & World Report.
Innovative Cancer Clinical Trials, Close to Home
Cancer Clinical Trials, Near You
130
Cancer Clinical Trials
Ochsner conducts more than 130 cancer clinical trials every year.
A Day in the Life of the Cancer Experts at Ochsner
Ochsner Doctor's Note: Marc Matrana, MD - Precision Cancer Therapies Program
Cancer Clinical Trials Patient Testimonial - Gibson Sewell
Cancer Clinical Trials Patient Testimonial - Sonia Suazo
Clinical Trials with Dr. Marc Matrana
Hello Health: Marc Matrana, Oncology
Hello Health: Precision Cancer Therapies Program with Marc Matrana, MD
Hello Health: New Treatments for Advanced Cancer with Marc Matrana, MD
Groundbreaking Clinical Trials for Cancer Patients
Our Location
Gayle and Tom Benson Cancer Center
1516 Jefferson Hwy.
New Orleans, LA 70121
Leading the Way in Cancer Care
Cancer Clinical Trials, Near You
The Ochsner Precision Cancer Therapies team provides the most advanced cancer care available and offers compassionate support to patients and their families.
Our Team
Our Team
The Leaders in Clinical Trials
We’re home to the largest clinical trials network in Louisiana, including early phase trials and a powerful partnership with TGen, a leading research institute. Plus, we're expanding our office space this year to give us even more room to serve our patients.
Access to Innovative Treatments
We offer clinical trials that aren’t available elsewhere. Plus, we offer the latest in treatment, research and advanced testing, so you won’t have to travel far to get the best cancer care possible.
Coordinated Care
An experienced and fully dedicated team of doctors, nurses, researchers and more works hand-in-hand with your physician, ensuring you receive comprehensive, collaborative care.
Personalized Treatment
As a patient, you’ll benefit from a customized care plan that is based on the most up-to-date research and your cancer’s unique genetic profile.
What Is a Clinical Trial and How Can It Help Me?
Learn how our cutting-edge research can translate into lifesaving care for you.
Advanced Care
Patients have access to additional services including free next generation sequencing; nutrition, psychological and palliative care support; and chemo care companion for high-risk monitoring at home.
Marc Matrana, MD, MS, FACP
Medical Director, Ochsner Precision Cancer Therapies Program
As the leader of the Ochsner Precision Cancer Therapies Program, Dr. Matrana focuses on treating patients with cancers of the genitourinary tract, lung cancer, gastrointestinal cancer, and other solid tumors. He is a native of New Orleans, who trained at MD Anderson Cancer Center in Houston where he served as Chief Fellow. His groundbreaking research has led to numerous peer-reviewed articles, chapters and other publications in the field of genitourinary medical oncology. In addition to research and patient care, Dr. Matrana is an active medical educator who has spoken to groups around the world.
Daniel Von Hoff, MD, FACP
Senior Consultant
Dr. Von Hoff is currently Physician-in-Chief and Distinguished Professor at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. Dr. Von Hoff’s major interest is in the development of anticancer agents. He is a winner of the prestigious Karnofsky award for outstanding achievements in cancer research and impact on treatment of cancer patients.
Daniel Johnson, MD
Deputy Medical Director, Ochsner Precision Cancer Therapies Program
Dr. Johnson, medical oncologist, specializes in treating melanoma patients and has special research interests in strategies to overcome immunotherapy resistance and prevent immune related adverse events. He has multiple peer-reviewed articles and presentations at national meetings pertaining to the management and underlying mechanisms of immune toxicity. Dr. Johnson is a clinical investigator focused on designing and implementing clinical trials intended to optimize the safety and efficacy of immune checkpoint inhibitors.
Laura Finn, MD
Deputy Medical Director, Hematology, Precision Cancer Therapies Program
Dr. Finn is the Interim Director of Ochsner’s Hematology and Bone Marrow Transplant Program. She completed a Hematology/Oncology fellowship at the Mayo Clinic in Jacksonville, FL where she was chief fellow and remained on faculty for two years as an Assistant Professor of Medicine. She completed advanced training in Bone Marrow Transplant at the University of Minnesota. She is the author of numerous peer reviewed publications in Hematology, Bone Marrow Transplant and use of Palliative Medicine in cancer care and speaks globally on these topics. As a clinical investigator, Dr. Finn is focused on therapeutic trials for the treatment of hematologic malignancies and enhancement of bone marrow transplant.
Katrina Wade, MD
Key Investigator
Dr. Katrina Wade’s area of clinical expertise is gynecologic cancers, including cervical, uterine, vulvar and ovarian cancer, as well as gestational trophoblastic disease. She is board certified in Gynecologic Oncology and has been recognized for her research in the field of gynecologic oncology. She is widely published in peer-reviewed medical journals and serves on the Ovarian Cancer committee for NRG oncology. Dr. Wade strongly believes in a multidisciplinary team approach to gynecologic cancer care. She seeks to provide women with the most advanced and personalized treatment plans while best preserving quality of life.
Erin Pierce, MSN, APRN, FNP-C
Key Investigator
Erin Pierce received a Master of Science in Nursing from the University of South Alabama and a Bachelor of Science in Nursing from Louisiana State University. She serves as a sub-investigator on clinical trials and collaborates with physicians to care for patients enrolled in the Precision Cancer Therapies Program. Her special areas of interest are genitourinary and early phase clinical trials. She was chosen as the 2018 Ochsner Advanced Practice Provider of the Year for her research contributions.
John Cole, MD
Medical Director of Oncology Research
Completed his Hematology /Oncology Fellowship at Columbia Presbyterian Medical Center in New York. He joined the Ochsner faculty in 1989. He has been Principal Investigator of the Ochsner NCORP since 2017 and is currently the Director of Clinical Cancer Research for Ochsner Health System. His major personal research focus is on Breast Cancer clinical trials.
Brian A. Moore, MD, FACS
Medical Director, Ochsner Cancer Institute
Dr. Moore is OHS Cancer Center Director and Chairman of the ENT Department. After a residency in Otolaryngology-Head and Neck surgery at Vanderbilt, he completed a fellowship at MD Anderson Cancer Center in Head and Neck Surgical Oncology and Reconstruction. He has published numerous papers and book chapters related to surgical reconstruction and head and neck cancers. His clinical interests include advanced skin cancer/melanoma, salivary gland disorders and thyroid/parathyroid disorders.
